Citation Impact
Citing Papers
Molecular Analysis of Commensal Host-Microbial Relationships in the Intestine
2001 StandoutScience
Abolition of Long-Term Stability of New Hippocampal Place Cell Maps by NMDA Receptor Blockade
1998 StandoutScienceNobel
Mutant G-protein-coupled receptors as a cause of human diseases
2004
The Antinociceptive and Sedative Effects of Carbachol and Oxycodone Administered into Brainstem Pontine Reticular Formation and Spinal Subarachnoid Space in Rats
2001
Development of Muscarinic Analgesics Derived from Epibatidine: Role of the M4 Receptor Subtype
1999
RIM1α and Interacting Proteins Involved in Presynaptic Plasticity Mediate Prepulse Inhibition and Additional Behaviors Linked to Schizophrenia
2010 StandoutNobel
The neural basis of drug craving: An incentive-sensitization theory of addiction
1993 Standout
Role of glutamate in schizophrenia: integrating excitatory avenues of research
2008
Metabotropic Glutamate Receptor 8-Expressing Nerve Terminals Target Subsets of GABAergic Neurons in the Hippocampus
2005
Combined Blockade of Cholinergic Receptors Shifts the Brain from Stimulus Encoding to Memory Consolidation
2006
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
The cholinergic hypothesis of Alzheimer's disease: a review of progress
1999 Standout
Management of acute organophosphorus pesticide poisoning
2007 Standout
Sjögren's syndrome
2005 Standout
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
2008 Standout
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
2004
The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease
1998
In the formalin model of tonic nociceptive pain, 8-OH-DPAT produces 5-HT1A receptor-mediated, behaviorally specific analgesia
2001
Cloning of a novel glutamate receptor subunit, GluR5: Expression in the nervous system during development
1990
Descending control of pain
2002 Standout
Schizophrenia
2009 Standout
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
1998
Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment
2002 Standout
Mechanical, thermal and formalin-induced nociception is differentially altered in 5-HT1A−/−, 5-HT1B−/−, 5-HT2A−/−, 5-HT3A−/− and 5-HTT−/− knock-out male mice
2007 StandoutNobel
The memory function of sleep
2010 Standout
The Science of Stroke: Mechanisms in Search of Treatments
2010 Standout
Identification of an Allosteric Binding Site for Zn2+on the β2 Adrenergic Receptor
2002 StandoutNobel
Contributions of the Amygdala to Emotion Processing: From Animal Models to Human Behavior
2005 Standout
The Presynaptic Active Zone
2012 StandoutNobel
Positive Cooperativity of Acetylcholine and Other Agonists with Allosteric Ligands on Muscarinic Acetylcholine Receptors
1997
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia
2000 StandoutNobel
Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist
2012 StandoutNatureNobel
The Rise and Fall of the Chemoattractant Receptor GPR33
2005 StandoutNobel
Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
2004 Standout
Animal models of drug craving
1993
Alzheimer's disease
2006 Standout
Role of spinal 5‐HT1A receptors in morphine analgesia and tolerance in rats
2003
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
2009
The induction of pain: an integrative review
1999
Alzheimer's Disease
2010 Standout
Major Depressive Disorder
2008 Standout
M1 Agonists for the Treatment of Alzheimer's Disease.
1996
Alzheimer's Disease
2004 Standout
Structure and dynamics of the M3 muscarinic acetylcholine receptor
2012 StandoutNatureNobel
The Antiallodynic Effects of Intrathecal Cholinesterase Inhibitors in a Rat Model of Neuropathic Pain
1999
Drug Dependence, a Chronic Medical Illness
2000 Standout
Cholinesterase Inhibitors for Alzheimer??s Disease
2001
Tolerance and selective cross-tolerance to the motivational effects of opioids
1988
The amyloid state and its association with protein misfolding diseases
2014 Standout
Nociceptors: the sensors of the pain pathway
2010 StandoutNobel
Involvement of Acetylcholine in the Nucleus Accumbens in Cocaine Reinforcement
1999
In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist
1997
Homeostasis of Eye Growth and the Question of Myopia
2004 Standout
Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors.
1994
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
2005 Standout
Treatment of the Neuropsychiatric Symptoms in Alzheimer's Disease
2003
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Evidence for multiple opiate receptor involvement in different phencyclidine-induced unconditioned behaviors in rats
1986
Glutamatergic Enteric Neurons
1997
Hyperactivity and Intact Hippocampus-Dependent Learning in Mice Lacking the M1Muscarinic Acetylcholine Receptor
2001
Alzheimer's disease
1998 Standout
Evidence for an endogenous peptide ligand for the phencyclidine receptor
1984
CENTRAL CHOLINERGIC SYSTEMS AND COGNITION
1997
Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology
1989 StandoutNature
Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia.
1996 Standout
Comparison of the pharmacologic effects of N-allylnormetazocine and phencyclidine: Sensitization, cross-sensitization, and opioid antagonist activity
1986
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy
2006
Pyrazolpquinolines: second generation benzodiazepine receptor ligands have heterogeneous effects
1987
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
1997 Standout
Impaired Thermosensation in Mice Lacking TRPV3, a Heat and Camphor Sensor in the Skin
2005 StandoutScienceNobel
Alternative splicing generates functionally distinct N-methyl-D-aspartate receptors.
1992 StandoutNobel
Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer’s disease
2000
Drug Abuse: Hedonic Homeostatic Dysregulation
1997 StandoutScience
About Sleep's Role in Memory
2013 Standout
State-dependent learning and drug discriminative control of behaviour: An overview
1986
Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine.
1984
Physical Activity and Public Health in Older Adults
2007 Standout
Current and Novel Approaches to the Drug Treatment of Schizophrenia
2001
The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
1986 Standout
Emerging drugs for schizophrenia
2008
The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway
2001 StandoutNobel
Altered expression of renal AQPs and Na+transporters in rats with Lithium-induced NDI
2000
Muscarinic Receptor Agonists and Antagonists
2001
Muscarinic Receptor Agonists in Alzheimer??s Disease
1999
Recent advances in the phencyclidine model of schizophrenia
1991 Standout
A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease
1999
Naloxone-inaccessible sigma receptor in rat central nervous system.
1983
The selective muscarinic M1 agonist AF102B decreases levels of total A? in cerebrospinal fluid of patients with Alzheimer's disease
2000
Aquaporins in the Kidney: From Molecules to Medicine
2002 StandoutNobel
Buprenorphine treatment of opioid dependence: A review.
1995
The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew.
1996
Molecular Diversity of Glutamate Receptors and Implications for Brain Function
1992 StandoutScience
Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes
1992 StandoutScienceNobel
Works of H E Shannon being referenced
M1 Receptor Agonist Activity Is Not a Requirement for Muscarinic Antinociception
1997
Discriminative stimulus effects of diazepam in rats: evidence for a maximal effect.
1983
Pharmacological analysis of the phencyclidine-like discriminative stimulus properties of narcotic derivatives in rats.
1982
Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
1994
A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice.
1990
Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor
2002
Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice
2004
Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease
1997
Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore
1992
Yohimbine produces antinociception in the formalin test in rats: involvement of serotonin 1A receptors
2000
Differential diazepam-antagonist effects of the benzodiazepine receptor ligand CGS 9895 in rodents.
1985
Evaluation of phencyclidine analogs on the basis of their discriminative stimulus properties in the rat.
1981
Glutamate receptors of the N-methyl-D-aspartate subtype in the myenteric plexus of the guinea pig ileum.
1989
The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
1997
Comparison of behavior maintained by intravenous cocaine and d-amphetamine in dogs.
1984
Evaluation of the discriminative effects of morphine in the rat.
1976
3-(3-Alkylthio-1,2,5-thiadiazol-4-yl)-1-azabicycles. Structure—activity relationships for antinociception mediated by central muscarinic receptors
1996
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
1994
Pharmacological evaluation of N-allynormetazocine (SKF 10,047) on the basis of its discriminative stimulus properties in the rat.
1983
The tetrahydropyridine ring confers optimal M-1 selectivity and blood brain barrier penetration among hexyloxy-1,2,5-thiadiazole azacycles
1997
Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: quantitative antagonism by naloxone.
1984
Comparative behavioral and neurochemical activities of cholinergic antagonists in rats.
1993
Behavioral pharmacology of olanzapine: a novel antipsychotic drug.
1997
Structure-activity relationship studies of phencyclidine derivatives in rats.
1984
Determination of the intrinsic functional muscarinic activity of xanomeline
1999